ClinicalTrials.gg
RecruitingNCT07225049Updated Jun 15, 2026

Integrated PTSD and Chronic Pain Treatment

An interventional study of Integrated Treatment for PTSD and Chronic Pain in PTSD and Chronic Pain, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Weill Medical College of Cornell University.

Planned enrollment
8th of 12
20 · median 23
Started
2025
the only one that year
No phase
7 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 14th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stress Disorders, Post-Traumatic by Weill Medical College of Cornell University, or all of them as a file.
02

Study summary

Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions. Gold standard treatments exist for both PTSD (e.g., Prolonged Exposure; PE) and chronic pain (e.g., Cognitive Behavioral Therapy for Chronic Pain; CBT-CP) and are generally offered sequentially (i.e., one at a time for the condition that is most prominent). Treating these conditions separately may overlook their interconnected nature, which may reduce efficacy and increase dropout. Thus, there is a need for an intervention to target both simultaneously, which may be more effective and efficient than treating conditions sequentially.

This is a single-arm pilot study to assess the feasibility and acceptability of an integrated treatment for adults with comorbid PTSD and chronic pain. The intervention consists of 12 90-minute virtual psychotherapy sessions scheduled twice per week. The treatment draws from modules in PE and CBT-CP including psychoeducation, exposure to feared/avoided situations and activities, processing of exposures, behavioral activation, breathing and relaxation techniques, sleep hygiene, symptom monitoring, and structured homework assignments. Baseline and post-treatment assessments will be conducted.

03

Conditions studied

  • PTSD
  • Chronic Pain

Keywords

  • PTSD
  • Chronic Pain
  • Integrated Treatment
  • Comorbidity
  • Prolonged Exposure
  • CBT for Chronic Pain
  • Cognitive Behavioral Therapy for Chronic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • English-speaking
  • Currently meets criteria for PTSD, assessed by the CAPS-5 (any trauma type) - Chronic pain, assessed by greater than or equal to 4 on a scale of 0-10 pain severity over the past 3 months
  • Medically stable at the time of study enrollment (chronic illness and disability does not prevent attendance of outpatient therapy sessions)
  • Stable on psychotropic medication for past 60 days
  • Agreed to not change current medication or pain-related treatments over the course of the study unless medically necessary
  • Must be located in the state of New York for virtual assessments and treatment sessions

Exclusion criteria

Exclusion Criteria:

  • Lifetime diagnosis of schizophrenia, other psychotic disorder, or bipolar I disorder
  • Participation in concurrent evidence-based psychological treatment for PTSD or chronic pain during the past 3 months
  • Participants must not participate in an evidence-based psychological treatment for either PTSD or pain during the course of the study.
  • Moderate or severe substance use in the past 90 days
  • Cognitive impairment to the degree that the patient cannot provide or fill out assessment measures
  • Participants who in the PI's judgement pose a current homicidal or suicidal risk
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Integrated PTSD and Chronic Pain Treatment

    Integrated treatment combining modules from Prolonged Exposure Therapy with Cognitive Behavioral Therapy for Chronic Pain

    Behavioral: Integrated Treatment for PTSD and Chronic Pain

Interventions

  • BehavioralIntegrated Treatment for PTSD and Chronic Pain

    The intervention consists of 12 90-minute virtual psychotherapy sessions scheduled twice per week. The treatment integrates modules from Prolonged Exposure and Cognitive Behavioral Therapy for Chronic Pain.

06

What researchers measure

Primary outcomes

  1. Feasibility Indicator: Number of Participants Screened

    Feasibility assessment will include number of participants screened defined as number of individuals who complete our initial eligibility screener.

    Time frame: Baseline

  2. Feasibility Indicator: Enrollment

    Feasibility assessment will include enrollment defined as number of participants signing the informed consent form.

    Time frame: Baseline

  3. Feasibility Indicator: Number of Sessions Attended

    Feasibility assessment will include the number of sessions attended on average (out of 12).

    Time frame: Post-Treatment Assessment at approximately 6 weeks

  4. Feasibility Indicator: Attrition Percentage

    A feasibility measure of attrition will be assessed by examining the percent of individuals who did not complete all 12 intervention sessions.

    Time frame: Post-Treatment Assessment at approximately 6 weeks

  5. Feasibility Indicator: Number of Assessments Attended

    A feasibility indicator of number of assessments (baseline and post-treatment) attended will be measured.

    Time frame: Baseline and Post-Treatment Assessment at approximately 6 weeks

  6. Feasibility Indicator: Percentage of Self-Reports Completed

    Self-reports are administered at each assessment (baseline and post-intervention) as well as every other treatment session (every 2 weeks up to 12 weeks). Therefore, there are 8 total self-report assessments and the percentage of those completed will be calculated.

    Time frame: Baseline, Post-Intervention at approximately 6 weeks, Every Other Treatment Session (Every 2 weeks up to 12 weeks)

  7. Intervention Satisfaction

    Intervention satisfaction will be rated with a Likert scale ranging from 1-10 with greater scores indicating higher satisfaction.

    Time frame: Post-Treatment Assessment at approximately 6 weeks

  8. Intervention Acceptability

    Intervention acceptability will be measured on a Likert scale ranging from 1-10 with greater scores indicating higher acceptability.

    Time frame: Post-Treatment Assessment at approximately 6 weeks

  9. Qualitative Intervention Feedback

    Open-ended questions that include assessing overall impressions of treatment, feedback on the frequency and length of sessions, challenges or barriers, likelihood of recommending this treatment to a friend, and comparison of this treatment to other treatments received in the past.

    Time frame: Post-Treatment Assessment at approximately 6 weeks

Secondary outcomes

  1. Change in Score on the Clinician Administered PTSD Score (CAPS-5)

    Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score. Total Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Baseline to approximately 6 weeks

  2. Change in Score on the PTSD Checklist for DSM-5 (PCL-5)

    The well-validated PCL-5 will assess self-reported PTSD symptom severity. Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Baseline to approximately 6 weeks

  3. Change in Score on the Pain Severity Subscale of the Brief Pain Inventory (BPI)

    Pain severity is a 4-item subscale with ranges from 0-10. Greater scores indicate higher pain severity.

    Time frame: Baseline to approximately 6 weeks

  4. Change in Score on the Pain Interference Subscale of the Brief Pain Inventory (BPI)

    Pain interference is a 7-item subscale with ranges from 0-10. Greater scores indicate greater pain interference.

    Time frame: Baseline to approximately 6 weeks

  5. Change in Score on the Pain Catastrophizing Scale (PCS)

    The 13-item PCS measure has scores ranging from 0-52, with higher scores indicating greater pain catastrophizing. Three subscales (rumination, magnification, and helplessness) are summed to form the total score.

    Time frame: Baseline to approximately 6 weeks

  6. Change in Score on the Chronic Pain Acceptance Questionnaire (CPAQ)

    This 20-item measure results in a total score ranging from 0-120 with high scores reflecting greater acceptance of pain. Two subscales (activity engagement and pain willingness) are summed to create the total score.

    Time frame: Baseline to approximately 6 weeks

  7. Change in Score on the Posttraumatic Cognitions Inventory (PTCI)

    The 33-item PTCI yields three subscores: negative cognitions about the self, negative cognitions about the world, and self-blame. Items are averaged so the range of scores for each subscale is 0-7 with higher scores representing more maladaptive cognitions. A total score is calculated by summing each of the 33 items yielding a score between 33-231, with higher scores indicating more maladaptive cognitions.

    Time frame: Baseline to approximately 6 weeks

  8. Change in Score on the Fear-Avoidance Components Scale (FACS)

    This 20-item measure results in total scores ranging from 0-100, with greater scores indicating more severe fear-avoidance beliefs.

    Time frame: Baseline to approximately 6 weeks

  9. Change in Score on the Anxiety Sensitivity Index (ASI-3)

    This 18-item measure results in a total score ranging from 0-72 with higher scores reflecting greater anxiety sensitivity. Three subscales (physical concerns, cognitive concerns, and social concerns) are summed to create a total score.

    Time frame: Baseline to approximately 6 weeks

  10. Change in Score on the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)

    The ASSIST is a questionnaire that screens for all levels of problem or risky substance use in adults including tobacco, alcohol, cannabis, cocaine, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opioids, and other drugs. A score for each substance ranges from 0-39 with higher scores indicating greater problems or risks related to substance use. A total score is not computed and instead, each substance will be analyzed individually.

    Time frame: Baseline to approximately 6 weeks

  11. Change in Score on the Expectancies for Alcohol Analgesia (EAA) Measure

    The EAA is a 5-item scale. Items are summed to generate a total score ranging from 0-45 with higher scores indicating greater expectancy for alcohol analgesia.

    Time frame: Baseline to approximately 6 weeks

  12. Change in Score on the Difficulties in Emotion Regulation Scale (DERS-18)

    This 18-item measure results in a total score ranging from 18-90 with higher scores reflecting greater difficulties with emotion regulation.

    Time frame: Baseline to approximately 6 weeks

  13. Change in Score on the Patient Health Questionnaire (PHQ-9)

    The PHQ-9 scores range from 0-27. Higher scores indicate greater symptom severity.

    Time frame: Baseline to approximately 6 weeks

  14. Change in Score on the Insomnia Severity Index (ISI)

    7 item self-report measure. Total scores range from 0-28, with higher scores indicating higher insomnia severity.

    Time frame: Baseline to approximately 6 weeks

  15. Change in Score on the Multidimensional Assessment of Interoceptive Awareness (MAIA-2)

    This is a 37-item measure that results in 8 subscales: noticing, not-distracting, not-worrying, attention regulation, emotional awareness, self-regulation, body listening, and trust. Each subscale ranges from 0-5, where higher scores reflect more awareness of bodily sensations. A total score is not computed, and instead, each subscale is analyzed individually.

    Time frame: Baseline to approximately 6 weeks

  16. Change in Score on the Quality of Life Inventory (QOLI)

    The assessment yields an overall score and profile in 16 areas of life; health, self-esteem, goals and values, money, work, play, learning, creativity, helping, love, friends, children, relatives, home, neighborhood, and community. Subscales are computed by multiplying satisfaction (-3 to +3) by importance (0 to 2) and resulting scores are averaged to yield a total score ranging from -6 to +6, with higher scores indicate higher level of quality of life.

    Time frame: Baseline to approximately 6 weeks

  17. Change in Score on the Religious and Spiritual Struggles Scale (RSS-5)

    This is a 5-item questionnaire measuring the extent to which one experiences conflict or struggle with spirituality or religious faith. Each item is rated on a scale from 1 (Not at All) to 5 (A Great Deal), thus higher scores indicate more spiritual struggle.

    Time frame: Baseline to approximately 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 20 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2025
First posted
Nov 5, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225049
Responsible party
Sponsor
First posted
Nov 5, 2025
Start date
Dec 8, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Mariel Emrich, MS
Contact
mae2050@med.cornell.edu
212-821-0783
JoAnn Difede, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion